Format

Send to

Choose Destination
Expert Opin Biol Ther. 2012 Mar;12(3):343-51. doi: 10.1517/14712598.2012.657622. Epub 2012 Jan 28.

Obinutuzumab for the treatment of lymphoproliferative disorders.

Author information

1
Tom Baker Cancer Centre & University of Calgary, 1331-29th St NW, Calgary, Alberta, Canada.

Abstract

INTRODUCTION:

Targeted therapy against CD20 with the mAb rituximab has led to significant improvements in survival for patients with B-cell non-Hodgkin's lymphoma (NHL). Despite these improvements, many patients relapse and/or become refractory after rituximab-containing therapies and thus better therapies are required for NHL.

AREAS COVERED:

Obinutuzumab is a novel, humanized, anti-CD20 mAb currently being investigated in Phase III studies in comparison to rituximab. An overview of obinutuzumab, its mechanisms of action and the results of pre-clinical and Phase I/II studies are presented.

EXPERT OPINION:

Pre-clinical studies suggest that obinutuzumab is a more potent anti-CD20 mAb than Rituximab at inducing antibody-dependent cellular cytotoxicity (ADCC) and direct cell death (DCD). Obinutuzumab is safe and effective in CD20 + NHL and further study is warranted. Results of ongoing Phase III clinical trials comparing Obinutuzumab to Rituximab in different disease settings and with different chemotherapy regimens are eagerly awaited.

PMID:
22283718
DOI:
10.1517/14712598.2012.657622
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center